University of British Columbia Okanagan
Kelowna, British Columbia, V1V 3G1, Canada
NCT Number: NCT04847999
Diabetes is a growing concern in the world with an estimated 9.3% of adults, ages 20-79, with it in 2019, type 2 diabetes accounting for 90% of this total. A common recommendation for individuals with diabetes is to limit sugars and sweets as it may cause a high blood glucose response. As a result, chocolate is often avoided due to the sugar content; though, high-polyphenol chocolate may have a beneficial effect on hyperglycaemia and vascular function. The sugar-free chocolate from Ross Chocolates is formulated with a blend of inulin, erythritol, and stevia. These alternatives to sugar are not expected to cause a significant change in blood glucose levels following consumption. The main objective of this study is to verify glucose levels before and after consumption of Ross Chocolates' blend of sweeteners dark chocolate and conventional chocolate in people with diabetes.
Looking for future studies?
Notify Me18 year–75 year
All sexes
Interventional
Not applicable
Kelowna, British Columbia, V1V 3G1, Canada
Individuals with type 1 or type 2 diabetes (10 participants each) will consume a Ross Chocolate or conventional sugar-sweetened dark chocolate bar on two occasions in a randomized crossover trial. Blood glucose levels will be measured by finger prick for 120 minutes after consumption to determine postprandial glucose excursions after consumption of each type of chocolate bar.
Due to the COVID-19 pandemic, the trial was converted to be completed remotely/virtually with participants completing the testing at their home under the supervision of a research team member who will describe the study procedures and monitor testing via video conferencing.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Dark chocolate
Time frame: 0 and 120 min after consumption of chocolate bar
A self-monitoring blood glucose device (OneTouch Verio IQ® kit Blood glucose monitoring system) will be used to measure blood glucose levels before and after consumption of chocolates. Incremental area under the curve will calculate the glucose above baseline fasting values across 120 minutes.
Time frame: 0 and 120 minutes after consumption of chocolate bar
Highest blood glucose value measured after consumption of the chocolate bar
Time frame: Throughout study completion: 0-120 minutes after consumption of chocolate bar
Highest blood glucose value above fasting baseline after consumption of the chocolate bar
Time frame: 0 and 120 minutes
A self-monitoring blood glucose device (OneTouch Verio IQ® kit Blood glucose monitoring system) will be used to measure blood glucose levels before and after consumption of chocolates. Total area under the curve will calculate the glucose above zero across 120 minutes.
Time frame: Throughout study completion:120 min after consumption of chocolate bar
Self-reported taste of chocolate bars will be assessed by questionnaire with ratings from awful (0), average (50) to fantastic (100).
University of British Columbia
Other
Impact of Dark Chocolate Consumption on Glucose Levels of People With Diabetes
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05229718
Autoimmune Diseases, Diabetes Mellitus
Boston, Massachusetts, United States
View Trial DetailsNCT07403565
Autoimmune Diseases, Diabetes Mellitus
Beijing, Beijing Municipality, China
View Trial DetailsNCT06418880
Autoimmune Diseases, Diabetes Mellitus
Stanford, California, United States
View Trial DetailsNCT05893797
Autoimmune Diseases, Diabetes Mellitus
Strasbourg, Alsace, France
View Trial Details